Postoperative Pain - Pipeline Insight, 2026

DelveInsight’s, “Postoperative Pain - Pipeline Insight, 2026” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Postoperative Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Postoperative Pain: Understanding

Postoperative Pain: Overview

Postoperative pain is a complex physiological and psychological response to surgery, typically resulting from tissue damage, inflammation, and the body's stress response. Effective management of postoperative pain is crucial for recovery, as uncontrolled pain can hinder healing, increase the risk of complications, delay recovery, and lead to chronic pain if not managed appropriately. The pain differs in quality and location from pain experienced prior to surgery, and is usually associated with iatrogenic neuropathic pain caused by surgical injury to a major peripheral nerve.

Acute pain occurs immediately after surgery and lasts for days to weeks due to tissue injury and inflammation. Chronic post-surgical pain (CPSP) persists for over three months, affecting 10-50% of patients depending on surgery type and risk factors. Neuropathic pain results from nerve damage during surgery, causing burning, tingling, or shooting sensations.

Surgery involves cutting tissues and nerves, triggering inflammation and changes in pain processing that can lead to chronic pain. Peripheral nerve injury increases sodium-channel expression in sensitized nerves, causing spontaneous activity and excess glutamate release. This glutamate acts on receptors (e.g., NMDA, AMPA), driving intracellular changes that sustain central sensitization, amplifying pain signals in the spinal cord and lowering response thresholds. Synaptic activity in spinal neurons increases, while signals from inflamed tissue affect the CNS and intracellular pathways, causing gene transcription changes in sensory neurons. This leads to heightened neuronal excitability, potentially resulting in structural and functional changes that transform pain into a disease over time. The intensity of postoperative pain varies based on surgery type, with major tissue trauma procedures like orthopedic, thoracic, and abdominal surgeries causing more severe pain. Individual factors such as age, sex, genetics, and past pain experiences influence pain sensitivity. Psychological factors, including anxiety, depression, and preoperative pain expectations, can further exacerbate pain perception.

Effective treatment of postoperative pain includes a number of factors, including good nursing, non-pharmacological techniques, such as distraction, and balanced (multimodal) analgesia to provide adequate pain relief with optimal drug combinations used at the lowest effective doses. Postoperative pain management should be step-wise and balanced. Balanced (multimodal) analgesia: Balanced (multimodal) analgesia uses two or more analgesic agents that act by different mechanisms to achieve a superior analgesic effect without increasing adverse events compared with increased doses of single agents.

Opioid Analgesia: The most commonly used intravenous opioids for postoperative pain are morphine, hydromorphone (dilaudid), and fentanyl. Morphine is the standard choice for opiates and is widely used. It has a rapid onset of action with peak effect occurring in 1 to 2 hours.

""Postoperative Pain- Pipeline Insight, 2026"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Postoperative Pain pipeline landscape is provided which includes the disease overview and Postoperative Pain treatment guidelines. The assessment part of the report embraces, in depth Postoperative Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postoperative Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Postoperative Pain R&D. The therapies under development are focused on novel approaches to treat/improve Postoperative Pain.

Postoperative Pain Emerging Drugs Chapters

This segment of the Postoperative Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Postoperative Pain Emerging Drugs

• PF614: Ensysce Biosciences

PF614 is an oxycodone-based pain medication that has been chemically modified to be inactive until swallowed where it uses one’s own digestive enzymes to activate and release oxycodone to fight pain. Oxycodone has been used for many years to help manage pain severe enough to require an opioid when other pain treatments do not treat pain well enough or you cannot tolerate them. The Ensysce TAAP™ chemical modification delivers pain-relieving medication in a similar manner as OxyContin but with a number of advantages. The pain relief from PF614 should last about 12 hours per dose and you can take it with or without food. Currently, the drug is in the Phase III stage of its development for the treatment of Postoperative Pain as per the company pipeline.

• ATX101: Allay Therapeutics

ATX101 is a novel investigational configuration of an approved, well-characterized, validated intracellular sodium ion channel blocker, bupivacaine, and a biopolymer that has been designed to provide weeks of pain relief following total knee arthroplasty (TKA, or replacement), a common orthopedic surgery. ATX101 has a high density of drug within its small footprint to allow for ultra-sustained analgesia. It is placed in minutes at the end of standard surgery to deliver its analgesic effect over weeks before eventually dissolving into water and carbon dioxide. The simple procedure does not require specialized training and is intended to replace the existing complex mix of analgesic products used for shorter-term pain management in the post-surgical setting. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Postoperative Pain.

• LC-400: LipoCure

LC-400 is an Ultra-Long-Acting Local Anesthetic (ULALA) developed by LipoCure, designed to provide extended post-operative pain relief with a single administration. It consists of a multi-vesicular liposome hydrogel formulation loaded with bupivacaine, enabling a slow and controlled drug release for prolonged analgesic effects while improving safety and efficacy. By maintaining sustained bupivacaine levels at the target site, LC-400 minimizes the need for additional analgesics like NSAIDs or opioids, reducing associated side effects. Phase I clinical studies have shown promising results, and the drug is advancing to Phase II trials.

• GB-6002: G2GBIO

G2GBIO's GB-6002 is an extended-release injectable formulation utilizing ropivacaine, designed for direct administration at the surgical site. This approach reduces systemic drug exposure compared to conventional administration methods, thereby minimizing side effects while aiming to provide pain relief for more than three days with a single dose. The company has completed a clinical pharmacology study domestically, confirming favorable pharmacokinetic results, safety, and tolerability. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Postoperative Pain.

Further product details are provided in the report……..

Postoperative Pain: Therapeutic Assessment

This segment of the report provides insights about the different Postoperative Pain drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Postoperative Pain
• There are approx. 40+ key companies which are developing the therapies for Postoperative Pain. The companies which have their Postoperative Pain drug candidates in the most advanced stage, i.e. Phase III include, Ensysce Biosciences
• Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Postoperative Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Postoperative Pain: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Postoperative Pain therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Postoperative Pain drugs.

Postoperative Pain Report Insights

• Postoperative Pain Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Postoperative Pain Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Postoperative Pain drugs?
• How many Postoperative Pain drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Postoperative Pain?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Postoperative Pain therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Postoperative Pain and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ensysce Biosciences
• Nevakar
• Sustained Therapeutics
• Concentric Analgesics
• G2GBIO
• LipoCure
• Bexson Biomedical
• Allay Therapeutics

Key Products

• PF614
• NVK-009
• ST-01
• CA-008
• GB-6002
• LC-400
• BB-106
• ATX-201

Show more